Bejelentkezés Regisztrálj ingyen

Hancock Jaffe Laboratories Inc Est. EPS Q / Q

Mi az Hancock Jaffe Laboratories Inc Est. EPS Q / Q?

A Est. EPS Q / Q az Hancock Jaffe Laboratories Inc - -72.00%

Mi a Est. EPS Q / Q meghatározása?



A várható EPS negyedévenkénti növekedési üteme évről évre meghaladja a vállalat EPS-jének becsült növekedését a következő negyedévben az előző negyedévhez képest.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Est. EPS Q / Q a Health Care szektor a NASDAQ-on cégekben a Hancock Jaffe Laboratories Inc -hoz képest

Mit csinál Hancock Jaffe Laboratories Inc?

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

est. eps q / q -hoz hasonló cégek Hancock Jaffe Laboratories Inc